Knowledge Distillery

Interim results from a phase 3 trial of the Moderna mRNA-1273 SARS-CoV-2 vaccine indicated 94% efficacy in preventing COVID-19.

Since the start of the vaccination campaign, the development of COVID-19 has been reported in persons who have received one or both doses of mRNA-1273…

• General interest

  •  

     

     

     

     

     

     

     

     

     

     

     

• Academic/Scientific

  •  

     

     

     

     

     

     

     

     

     

     

    …

CoV2 preS dTM is a stabilised pre-fusion spike protein vaccine produced in a baculovirus expression system being developed against SARS-CoV-2.

In this phase 1, double-blind, placebo-controlled, block-randomised trial the authors aimed to assess the safety and immunogenicity of an…

The COVID-19 pandemic is having profound mental health consequences for many people.

The comparative performance of different clinical sampling methods for diagnosis of SARS-CoV-2 infection by RT-PCR among populations with suspected…

A new variant of SARS-CoV-2, B.1.1.7, emerged as the dominant cause of COVID-19 disease in the UK from November, 2020.

Data on the efficacy of hydroxychloroquine or lopinavir-ritonavir for the treatment of high-risk outpatients with COVID-19 in developing countries are…

Acute ischemic stroke (AIS) is a known neurological complication in patients with respiratory symptoms of COVID-19 infection.

High-flow nasal oxygen is recommended as initial treatment for acute hypoxemic respiratory failure and is widely applied in patients with COVID-19.

The acute clinical manifestations of COVID-19 are well characterized; however, its post-acute sequalae have not been comprehensively described.